Determining whether Nautilus Biotechnology is an attractive purchase depends on an investor's willingness to absorb high volatility in pursuit of breakthrough technological rewards. The enterprise focuses heavily on developing a proprietary platform designed to quantify and analyze the human proteome at a single-molecule level. Because commercialization is complex and capital requirements are substantial, conservative investors typically view it as a high-risk growth opportunity suited for diversified portfolios.